JNJ trades around $223, still about 10% below the average analyst target of $250.58 and holding above the 200‑day moving average, indicating technical support near $220. The stock’s 2.9% dividend yield and solid Q1 earnings beat reinforce its fundamental strength.

Investor sentiment stays upbeat as J&J’s recent oncology data positions it to challenge AbbVie’s leading growth driver, easing fears of a slowdown. The broader pharma enthusiasm, highlighted by Lilly’s shine, adds tailwinds to JNJ’s momentum.

Long‑term, J&J’s diversified franchise and dividend‑aristocrat status offset litigation and competitive risks, supporting a steady ownership case. While the valuation premium to peers warrants caution, the overall outlook remains bullish.

The 10‑day RSI sits at 58 and MACD bullish crossover aligns with rising volume, signalling short‑term upside toward the $230 resistance. Statistical models project a 12% upside over the next month, consistent with a bullish stance.